A PLD2 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VU0364739

Item No. 42914

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[2-[1-(3-fluorophenyl)-4-oxo-1,3,8-triazaspiro[4.5]dec-8-yl]ethyl]-2-naphthalenecarboxamide
CAS Number
1244639-78-8
Molecular Formula
C26H27FN4O2
Formula Weight
446.5
Purity
≥98%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/ml
SMILES
O=C(C1=CC2=C(C=CC=C2)C=C1)NCCN3CCC4(CC3)C(NCN4C5=CC(F)=CC=C5)=O
InChi Code
InChI=1S/C26H27FN4O2/c27-22-6-3-7-23(17-22)31-18-29-25(33)26(31)10-13-30(14-11-26)15-12-28-24(32)21-9-8-19-4-1-2-5-20(19)16-21/h1-9,16-17H,10-15,18H2,(H,28,32)(H,29,33)
InChi Key
MSTXJJGAXXJCBY-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $54

    Add

    5 mg

    $203

    Add

    10 mg

    $297

    Add

    25 mg

    $539

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    VU036739 is an inhibitor of phospholipase D2 (PLD2; IC50 = 20 nM).1 It is selective for PLD2 over PLD1 (IC50 = 1,500 nM). VU036739 (10 µM) induces apoptosis in MDA-MB-231 breast cancer cells. It decreases levels of deoxyribonucleoside triphosphates in serum-starved U87MG glioma cells when used at a concentration of 5 µM.2 VU036739 (10 µM) inhibits arachidonic acid-induced increases in the production of prostaglandin E2 (PGE2) in MC3T3-E1 osteoblasts.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Lavieri, R.R., Scott, S.A., Selvy, P.E., et al. Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: Discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J. Med. Chem. 53(18), 6706-6719 (2010).

    2. Mathews, T.P., Hill, S., Rose, K.L., et al. Human phospholipase D activity transiently regulates pyrimidine biosynthesis in malignant gliomas. ACS Chem. Biol. 10(5), 1258-1268 (2015).

    3. Leis, H.J., and Windischhofer, W. Phospholipase D1 activity is crucial for cytosolic phospholipase A2 -dependent prostaglandin E2 formation in murine osteoblastic MC3T3-E1 cells. Prostaglandins Leukot. Essent. Fatty Acids 198-199, 102592 (2023).